Fluoxetine did not significantly improve the immune response in either model, only mitigating LPS-induced TLR4 elevation (Fig. 5A, B) and MS-induced IDO1 elevation (Fig. 5A, C), in addition to a slight inhibition of microglial activation in PFC (Fig. 6). This evidence concerns the gene IDO1 and myeloid sarcoma.